Group 1 - The company, Brainstorm Aurora-B (06681.HK), has entered into a placement and subscription agreement to issue 92 million shares at a price of HKD 5.6 per share, which represents a discount of approximately 12.09% compared to the last closing price of HKD 6.37 [1] - The placement shares account for about 7.27% of the company's existing issued share capital as of the announcement date [1] - The seller, ZTan Limited, is wholly owned by the company's executive director and chairman, Tan Zheng, who, along with his concert parties, holds a combined 40.95% stake in the company [1] Group 2 - The estimated total proceeds from the subscription are approximately HKD 515.2 million, with a net amount of about HKD 500.7 million expected [2] - The net proceeds are intended to be allocated as follows: approximately 50% for funding research and development programs, about 30% for domestic and international market development, and around 10% for general working capital purposes [2]

Group 1 - The company, Brainstorm Aurora-B (06681), has entered into a placement and subscription agreement, with a share placement price set at HKD 5.6 per share, representing a discount of approximately 12.09% from the last closing price of HKD 6.37 [1] - The placement shares will account for about 7.27% of the company's existing issued share capital as of the announcement date, and approximately 6.77% after the completion of the subscription [1] Group 2 - The total estimated proceeds from the subscription are approximately HKD 515 million, with a net amount expected to be around HKD 501 million after deducting all related costs and expenses [2] - The company plans to allocate approximately 50% of the net proceeds for research and development programs, including the development of non-invasive brain-computer interface systems and consumer-oriented digital health platforms, expected to be fully utilized by September 30, 2027 [2] - About 30% of the net proceeds will be used for domestic and international market development, including costs related to establishing national branches and supporting academic conferences, expected to be fully utilized by June 30, 2027 [2] - Approximately 10% of the net proceeds will be allocated for strategic investments and acquisitions within the digital health ecosystem, expected to be fully utilized by June 30, 2027 [2] - The remaining 10% will be used to supplement the company's general working capital, expected to be fully utilized by December 31, 2026 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 根據一般授權配售現有股份及先舊後新認購新股份 獨家整體協調人、配售代理及資本市場中介機構 董事會欣然宣佈，於2026年1月23日（交易時段前），本公司已訂立配售及認購 協議，配售及認購協議項下擬進行交易之所得款項總額合共估計約為515.20百 萬港元。 根據一般授權配售現有股份及先舊後新認購新股份 董事會欣然宣佈，於2026年1月23日（交易時段前），本公司、賣方及配售代理 訂立配售及認購協議，據此，(i)賣方已同意出售，而配售代理已同意作為賣方 之代理，盡力促使不少於六(6)名承配人按配售價每股配售股份5.6港元購買配售 股份，及(ii)賣方已有條件同意認購，而本公司已 ...

Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics (脑动极光-B, 06681) has seen significant stock activity, with shareholders depositing shares into Guotai Junan (Hong Kong), resulting in a market value of HKD 2.729 billion, accounting for 33.31% of the total [1] Group 2 - For the six months ending June 30, 2025, Brainstorm Cell Therapeutics reported revenue of HKD 100 million, representing a year-on-year increase of 92.82% [1] - The adjusted net loss for the company was HKD 88.022 million, which is an increase of 11.64% compared to the previous year [1] - The loss attributable to the company's owners was HKD 126 million, reflecting a year-on-year increase of 10.53%, with a loss per share of HKD 0.11 [1]

Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics Inc. (脑动极光-B) has deposited shares worth HKD 2.729 billion into Guotai Junan (Hong Kong), representing 33.31% of the total [1] - For the six months ending June 30, 2025, the company reported revenue of HKD 100 million, reflecting a year-on-year increase of 92.82% [1] - The adjusted net loss for the company was HKD 88.022 million, which is an increase of 11.64% compared to the previous year [1] - The loss attributable to the company's owners was HKD 126 million, marking a year-on-year increase of 10.53% [1] - The loss per share was reported at HKD 0.11 [1]

Group 1 - The core viewpoint of the news is the acceleration of the industrialization and commercialization of brain-computer interface (BCI) technology in China, supported by a joint policy from multiple government departments [1][2] - The policy emphasizes upgrading smart terminals and supporting breakthroughs in edge models and application toolchains, focusing on AI-enabled devices such as smartphones, computers, tablets, and smart home products [1] - The global BCI industry is experiencing rapid development, with a competitive landscape where the U.S. leads in invasive technologies while China excels in non-invasive approaches [2] Group 2 - Recent announcements from companies like Neuralink indicate plans for large-scale production of BCI devices by 2026, highlighting advancements in fully automated surgical processes [1] - The BCI industry encompasses a wide range of sectors, including materials, chips, surgery, and medical rehabilitation, with significant policy support and healthcare pricing measures in place to facilitate commercialization in China [1][2] - Key competitive factors in the BCI industry include electrodes, chips, and algorithms, with a focus on non-invasive commercialization in the short term and a shift towards flexible electrodes and high-throughput low-power chips in the long term [2]

Group 1 - The core viewpoint of the article highlights a significant decline in brain-computer interface concept stocks, with notable drops in companies such as Nanjing Panda Electronics, Lens Technology, BrainCo, and Micron Brain Science [1] - Nanjing Panda Electronics reported an 8.29% drop to HKD 5.53, while Lens Technology fell by 5.74% to HKD 28.26, BrainCo decreased by 5.7% to HKD 7.11, and Micron Brain Science dropped by 2.23% to HKD 13.15 [1] - Nanjing Panda has stated that its main business focuses on smart transportation, safe cities, industrial internet, and green service-oriented electronic manufacturing, with no current changes or mature products related to brain-computer interfaces [1] Group 2 - Wanlian Securities indicated that the commercialization of brain-computer interfaces is currently more focused on non-invasive methods, while the long-term core lies in (semi) invasive technologies, including flexible electrodes and high-throughput low-power chips [1] - Future industry development catalysts include policy support, medical insurance payments, breakthroughs in clinical registration nodes, core technology advancements, and domestic replacements [1] - For invasive methods, attention should be on research teams, clinical resources, and financing environments, while non-invasive methods should focus on branding, distribution channels, and cost control [1]

Core Viewpoint - The latest data from the Hong Kong Stock Exchange indicates that shareholders of Brainstorm Cell Therapeutics-B (06681) deposited shares worth HKD 742 million into HSBC Hong Kong, representing 8.13% of the total [1] Financial Performance - For the six months ending June 30, 2025, Brainstorm Cell Therapeutics reported revenue of HKD 100 million, reflecting a year-on-year increase of 92.82% [1] - The adjusted net loss for the company was HKD 88.022 million, which is an increase of 11.64% compared to the previous year [1] - The loss attributable to the company's owners was HKD 126 million, marking a year-on-year increase of 10.53% [1] - The loss per share was HKD 0.11 [1]

Core Viewpoint - The stock of Brainstorm Cell Therapeutics Inc. (脑动极光-B) experienced a significant increase of nearly 10%, reaching a peak price of 8.14 HKD per share, with a total market capitalization of approximately 10 billion HKD as of January 8, 2026 [1][2]. Group 1: Stock Performance - The stock opened at 7.46 HKD and reached a maximum price of 8.14 HKD, with a closing price of 7.21 HKD the previous day [2]. - The stock's 52-week high is 17.79 HKD, while the 52-week low is 3.51 HKD [2]. - The trading volume was 39.6 million shares, with an external trading volume of 22.58 million and an internal trading volume of 17.02 million [2]. Group 2: Company Developments - Brainstorm Cell Therapeutics announced on January 7 that it has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2]. - The company, in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has received approval to establish the "Beijing Key Laboratory for Precision Intelligent Diagnosis and Treatment of Mental Disorders" [1][2].

Group 1 - Brain-computer interface concept stocks saw a majority increase in early trading [1][2] - Brain洞极光-B (06681) rose by 9.57%, reaching HKD 7.90 [1][2] - 微创脑科学 (02172) increased by 6.76%, trading at HKD 13.26 [1][2] - 脑洞科技 (02203) experienced a rise of 9.33%, priced at HKD 0.246 [1][2]